Dr. Robert Droder, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Hahnemann University College of Medicine (1985)
- Years since graduation
- 41
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 591
Licensed in Texas since 1996, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1985Medical school: Hahnemann University College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license K0723 (first issued 1996; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Christus Mother Frances Hospital Tyler, TX
- Ut Health East Texas Tyler Regional Hospital Tyler, TX
- Ut Health East Texas Athens Hospital Athens, TX
- University of Texas Health Science Center at Tyler Tyler, TX
- Ut Health East Texas Quitman Hospital Quitman, TX
Medical groups
- University of Texas Health Science Center at Tyler-Facilty-Physician (122 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 591
- Services billed
- 1,603
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 654 | 376 |
| Established patient office or other outpatient visit, 40-54 minutes | 331 | 142 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 182 | 63 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 110 | 55 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 87 | 20 |
| New patient office or other outpatient visit, 60-74 minutes | 79 | 79 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 51 | 19 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 36 | 13 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Tyler, TX | 199 |
| Anastrozole Other prescribers in Tyler, TX | 144 |
| Prednisone Other prescribers in Tyler, TX | 116 |
| Xarelto (rivaroxaban) Other prescribers in Tyler, TX | 94 |
| Ondansetron Hcl Other prescribers in Tyler, TX | 91 |
| Dexamethasone Other prescribers in Tyler, TX | 75 |
| Gabapentin Other prescribers in Tyler, TX | 74 |
| Alprazolam Other prescribers in Tyler, TX | 67 |
| Potassium Chloride Other prescribers in Tyler, TX | 64 |
| Eliquis (apixaban) Other prescribers in Tyler, TX | 59 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 20 payments worth $450 in total to this clinician.
| AbbVie Inc. | $269 |
|---|---|
| Array Biopharma Inc | $78.07 |
| Novartis Pharmaceuticals Corporation | $60.76 |
| Myriad Genetic Laboratories, Inc. | $27.78 |
| Aveo Pharmaceuticals, Inc. | $14.31 |
| Food and Beverage | $450 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 7 companies. The companies reported $395,526 in research payments for these studies, mostly to the institutions running them.
- An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Participants with HR,HER2-Unresectable Locally Advanced or Metastati…
Merck Sharp & Dohme LLC - A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative…
Merck Sharp & Dohme LLC - A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage…
E.r. Squibb & Sons, L.l.c. - An interventional openlabel randomized multicenter phase 3 study of PF07220060 plus letrozole compared to CDK46 inhibitor plus letrozole in participants over 18 years of age with hormone receptor hrpositive HER2NEGATI…
Pfizer Inc. - A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06091254 - Neoadjuvant NSCLC
Genentech, Inc. - A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Epizyme, Inc. · Active, not recruiting · NCT04224493 - Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage Non Small Cell Lung Cancer
E.r. Squibb & Sons, L.l.c. - A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
E.r. Squibb & Sons, L.l.c. · Completed · NCT04623775 - DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
Daiichi Sankyo Inc. · Active, not recruiting · NCT04042701
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.